Additional Relevant Details “CLL patients with the genetic alteration del 17p are considered to be high risk and typically have poor prognoses,” said Dr. Stilgenbauer. “IMBRUVICA was the first therapy approved specifically for this difficult-to-treat patient population and the positive data seen in this analysis reinforce its clinical utility in CLL patients with del 17p.”